CANbridge Pharmaceuticals Inc. 1228.HK Stock
CANbridge Pharmaceuticals Inc. Price Chart
CANbridge Pharmaceuticals Inc. 1228.HK Financial and Trading Overview
CANbridge Pharmaceuticals Inc. stock price | 0.31 HKD |
Previous Close | 1.74 HKD |
Open | 1.7 HKD |
Bid | 1.57 HKD x N/A |
Ask | 1.66 HKD x N/A |
Day's Range | 1.52 - 1.7 HKD |
52 Week Range | 1.3 - 4.2 HKD |
Volume | 30K HKD |
Avg. Volume | 44.43K HKD |
Market Cap | 666.14M HKD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.96 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.23 HKD |
1228.HK Valuation Measures
Enterprise Value | 430.44M HKD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 8.435122 |
Price/Book (mrq) | 2.15956 |
Enterprise Value/Revenue | 5.451 |
Enterprise Value/EBITDA | -0.959 |
Trading Information
CANbridge Pharmaceuticals Inc. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -55.38% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.2 HKD |
52 Week Low | 1.3 HKD |
50-Day Moving Average | 1.75 HKD |
200-Day Moving Average | 2.33 HKD |
1228.HK Share Statistics
Avg. Volume (3 month) | 44.43K HKD |
Avg. Daily Volume (10-Days) | 22K HKD |
Shares Outstanding | 424.29M |
Float | 240.88M |
Short Ratio | N/A |
% Held by Insiders | 40.30% |
% Held by Institutions | 38.26% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -579.91% |
Gross Margin | 61.91% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -35.90% |
Return on Equity (ttm) | -96.50% |
Income Statement
Revenue (ttm) | 78.97M HKD |
Revenue Per Share (ttm) | 0.19 HKD |
Quarterly Revenue Growth (yoy) | 133.20% |
Gross Profit (ttm) | N/A |
EBITDA | -448844000 HKD |
Net Income Avi to Common (ttm) | -483475008 HKD |
Diluted EPS (ttm) | -1.28 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 463.11M HKD |
Total Cash Per Share (mrq) | 1.09 HKD |
Total Debt (mrq) | 155.28M HKD |
Total Debt/Equity (mrq) | 50.33 HKD |
Current Ratio (mrq) | 1.816 |
Book Value Per Share (mrq) | 0.727 |
Cash Flow Statement
Operating Cash Flow (ttm) | -280979008 HKD |
Levered Free Cash Flow (ttm) | -142036992 HKD |
Profile of CANbridge Pharmaceuticals Inc.
Country | Hong Kong |
State | N/A |
City | Suzhou |
Address | Unit 18, 6th Floor |
ZIP | N/A |
Phone | 86 10 8414 8018 |
Website | https://www.canbridgepharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 117 |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.
Q&A For CANbridge Pharmaceuticals Inc. Stock
What is a current 1228.HK stock price?
CANbridge Pharmaceuticals Inc. 1228.HK stock price today per share is 0.31 HKD.
How to purchase CANbridge Pharmaceuticals Inc. stock?
You can buy 1228.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CANbridge Pharmaceuticals Inc.?
The stock symbol or ticker of CANbridge Pharmaceuticals Inc. is 1228.HK.
Which industry does the CANbridge Pharmaceuticals Inc. company belong to?
The CANbridge Pharmaceuticals Inc. industry is Biotechnology.
How many shares does CANbridge Pharmaceuticals Inc. have in circulation?
The max supply of CANbridge Pharmaceuticals Inc. shares is 424.52M.
What is CANbridge Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
CANbridge Pharmaceuticals Inc. PE Ratio is now.
What was CANbridge Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
CANbridge Pharmaceuticals Inc. EPS is -0.96 HKD over the trailing 12 months.
Which sector does the CANbridge Pharmaceuticals Inc. company belong to?
The CANbridge Pharmaceuticals Inc. sector is Healthcare.